← Back to Search

Cannabinoid

THC-Based Medication for Agitation in Alzheimer's (IGC-AD1-P2 Trial)

Phase 2
Recruiting
Led By Dr Ismael Toro Grajales, MD
Research Sponsored by IGC Pharma LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to week six
Awards & highlights

Summary

This trial tests a natural THC-based medicine called IGC-AD1, given in small doses regularly. It targets people aged 60 and above with Alzheimer's-related dementia who have been experiencing agitation. The THC in the medicine helps reduce agitation by interacting with brain signals. The most recent trial reported significant improvement in agitation using nabilone.

Who is the study for?
This trial is for adults with mild to severe Alzheimer's dementia experiencing significant agitation. Participants must have a caregiver able to assist and use electronic devices, be on stable behavioral medications for 3 months, and consent to genetic testing. Women should not be of childbearing potential.
What is being tested?
The study tests IGC-AD1, a natural THC-based oral medication given in micro doses twice daily against a placebo, to manage symptoms of agitation in Alzheimer's patients.
What are the potential side effects?
Potential side effects may include typical reactions associated with THC such as drowsiness, changes in appetite or mood, dry mouth, and possibly disorientation or confusion.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to weeks two and six
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to weeks two and six for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Agitation
Secondary study objectives
Acute Agitation
Other study objectives
Agitation at week four
CYP2C9 polymorphisms on agitation
Caregiver burden
+6 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Active Comparator: IGC-AD1ActiveActive Control1 Intervention
IGC-AD1 Active Treatment THC plus another API plus excipients.
Group II: Placebo Comparator: IGC-AD1 PlaceboPlacebo Group1 Intervention
IGC-AD1 Placebo, similar to Active in color, taste, and texture, with excipients but without APIs.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for depression include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and atypical antidepressants. SSRIs and SNRIs work by increasing the levels of serotonin and norepinephrine in the brain, which are neurotransmitters associated with mood regulation. Atypical antidepressants may target a variety of neurotransmitter systems, including dopamine. The THC-based formulation in the IGC-AD1 trial interacts with the endocannabinoid system, which plays a role in mood, stress response, and emotional regulation. Understanding these mechanisms is crucial for depression patients as it helps tailor treatments to individual needs, potentially improving efficacy and reducing side effects.

Find a Location

Who is running the clinical trial?

IGC Pharma LLCLead Sponsor
1 Previous Clinical Trials
12 Total Patients Enrolled
Dr Ismael Toro Grajales, MDPrincipal InvestigatorInstituto Sanacoop
Natalia HernandezStudy DirectorInstituto Sanacoop

Media Library

IGC-AD1 (Cannabinoid) Clinical Trial Eligibility Overview. Trial Name: NCT05543681 — Phase 2
Memory Loss Research Study Groups: Active Comparator: IGC-AD1Active, Placebo Comparator: IGC-AD1 Placebo
Memory Loss Clinical Trial 2023: IGC-AD1 Highlights & Side Effects. Trial Name: NCT05543681 — Phase 2
IGC-AD1 (Cannabinoid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05543681 — Phase 2
~41 spots leftby Jun 2025